pharmaceutical companies

See the following -

Doctors Denounce Cancer Drug Prices Of $100,000 A Year

Andrew Pollack | New York Times | April 25, 2013

With the cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual step of banding together in hopes of persuading some leading pharmaceutical companies to bring prices down. Read More »

Doctors Given Meals by Drug Makers Prescribed More of Their Pills

Ed Silverman | STAT | June 20, 2016

Doctors who were fed meals costing even less than $20 later prescribed certain brand-name pills more often than rival medicines, according to a new analysis published on Monday of a federal database. And in most cases, costlier meals were associated with still higher prescribing rates for Medicare Part D drugs made by the same companies that provided the food. The findings, published in JAMA Internal Medicine, are likely to intensify an ongoing debate over the extent to which ties between drug makers and doctors unduly influence medical practice and the nation’s health care costs...

Read More »

Doctors' Dubious Excuses For Taking Pharmaceutical Companies' Money

Roy M. Poses | Health Care Renewal | March 19, 2013

Pro Publica has updated their database of payments by pharmaceutical payments to physicians and organizations.  It now has data from 15 companies totaling more than $2 billion from 2009 to 2012. To accompany Pro Publica's report, a number of news outlets wrote about payments given to local or regional doctors... Read More »

Dollars For Docs Mints A Millionaire

Tracy Weber and Charles Ornstein | ProPublica | March 11, 2013

Dr. Jon W. Draud, the medical director of psychiatric and addiction medicine at two Tennessee hospitals, pursues some eclectic passions. He’s bred sleek Basenji hunting dogs for show. And last summer, the Tennessee State Museum featured “African Art: The Collection of Jon Draud.” Read More »

Drug-resistant Superbugs Could Become Deadlier than Cancer

Ilene MacDonald | Fierce Healthcare | April 18, 2016

Superbugs are on track to kill 10 million people a year by 2050--more than those who die from cancer, warned UK Chancellor George Osborne, who urged for global and radical action to fight the threat from bacteria that have become resistant to antibiotics. These drug-resistant bugs are "an even greater threat to mankind than cancer," said Osborne, who was in the District of Columbia late last week during a meeting of the International Monetary Fund, The Guardian reported...

Read More »

Eli Lilly Offers Designers $75k To Redesign Clinical Trial Info For Patients

Fred Pennic | HIT Consultant | August 29, 2013

Eli Lilly opens Clinical Trial  Visualization Redesign Challenge for designers & developers to make clinical trial information more patient-friendly. Read More »

Epipen: A Sign of a Broken Healthcare System

Tanya Feke | Diagnosis Life, LLC | October 13, 2016

It has been going on for years. The difference is that now the media is hopping on the story. Now America is paying attention. In 2015, the price of doxycycline, a generic antibiotic, was up to $5 per pill, an increase from $0.03 in 2014. The antibiotic is the gold standard treatment for Lyme disease. In 2015, the price of Daraprim (pyrimethamine), was up to $750 per pill, an increase from $13.50. The antiparasitic medication is used to toxoplasmosis, an infection acquired in people who have HIV/AIDS...

Read More »

Five Ways Advanced Social Intelligence Guides Pharma Strategy

Mark Langsfield | PharmExec.com | June 4, 2013

Within the billions of daily comments from individuals across open social sources lies deep intelligence into markets, brands, patients, caregivers, healthcare providers and competitors. Several leading pharmaceutical companies are already using big data solutions to extract insights from the social realm... Read More »

From Open Source to Open Science

Kevin Lustig | pharmaphorum | August 17, 2012

Kevin Lustig explores open science and how it can be used to increase access to scientific data. Kevin also looks at how pharmaceutical companies, such as Pfizer and Merck, are promoting their own brand of open science. Read More »

Gathering a Health Care Industry Around an Open Source Solution: the Success of tranSMART

Andy Oram | EMR & EHR | May 18, 2015

The role of open source software in healthcare is relatively hidden and uncelebrated, but organizations such as the tranSMART Foundation prove that it is making headway behind the scenes. tranSMART won three awards at the recent Bio‐IT World conference, including Best in Show. The tranSMART Foundation is a non‐profit organization that develops creates software for translational research, performing tasks such as searching for patterns in genomes and how they are linked to clinical outcomes. Like most of the sustainable, highly successful open source projects, tranSMART avoids hiring programmers to do the work itself, but fosters a sense of community by coordinating more than 100 developers from the companies who benefit from the software.

Read More »

Getting To The Right Relationship Between Doctors And Drug Companies

David A. Shaywitz | Nextgov | May 8, 2013

The pharmaceutical industry is held in remarkably low esteem right now. It's seen as a bunch of nefarious pushers who pay off vulnerable doctors to prescribe their latest expensive, mediocre product. Physicians who work with pharma companies are considered especially suspect, routinely described as "cozy," "in bed with industry," and "on the take." Read More »

GGA Software Services Launches Open-Source Version Of Chemistry Electronic Lab Notebook

Press Release | GGA Software Services | September 26, 2012

GGA Software Services has released version 1.0 of Indigo ELN, the open-source version of the chemistry electronic lab notebook that was developed by one of the world's largest pharmaceutical companies. Read More »

Giant GSK Settlement Provides Reminder of the Pervasiveness of Stealth Marketing

Roy M. Poses | Health Care Renewal | July 5, 2012

The latest  and biggest legal settlement involving health care to hit the news, that of GlaxoSmithKline (GSK) and the US government, has many familiar elements. [These documents] provide good documentation about how pervasive systematic, deceptive stealth marketing campaigns have become in health care. Read More »

Global E-Clinical Trial Technologies Market to Reach US$1.37 Billion by 2018, According to New Report by Global Industry Analysts, Inc.

Press Release | Global Industry Analysts, Inc. | July 23, 2012

GIA announces the release of a comprehensive global report on the E-Clinical Trial Technologies markets. The global market for E-Clinical Trial Technologies is forecast to reach US$1.37 billion by the year 2018... Read More »

Global Wireless Health Market Expected To Reach $59.7 billion By 2018

Fred Pennic | HIT Consultant | September 3, 2013

The global wireless health market is currently valued at $23.8 billion in 2013 and is expected to reach $59.7 billion by 2018, at an estimated CAGR of 20.2% from 2013 to 2018, according to a new report by MarketsandMarkets. Read More »